All Outputs (9)

Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness (2022)
Journal Article
Simenacz, A., Wilmington, R., Green, C., Ardavani, A., & Idris, I. (2022). Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness. The British Journal of Diabetes, 22(2), 121-124. https://doi.org/10.15277/bjd.2022.350

Background: Glucagon-like peptide-1 analogues such as liraglutide 3.0 mg (Saxenda) have yielded significant weight loss in clinical trials when combined with lifestyle interventions. Despite the recent approval of liraglutide 3.0 mg, its success among... Read More about Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness.

Effects of GLP-1 Infusion Upon Whole-body Glucose Uptake and Skeletal Muscle Perfusion During Fed-state in Older Men (2022)
Journal Article
Abdulla, H., Phillips, B., Wilkinson, D., Gates, A., Limb, M., Jandova, T., …Atherton, P. (2023). Effects of GLP-1 Infusion Upon Whole-body Glucose Uptake and Skeletal Muscle Perfusion During Fed-state in Older Men. Journal of Clinical Endocrinology and Metabolism, 108(4), 971-978. https://doi.org/10.1210/clinem/dgac613

Introduction Ageing skeletal muscles become both insulin resistant and atrophic. The hormone glucagon-like peptide 1 (GLP-1) facilitates postprandial glucose uptake as well as augmenting muscle perfusion, independent of insulin action. We thus hypot... Read More about Effects of GLP-1 Infusion Upon Whole-body Glucose Uptake and Skeletal Muscle Perfusion During Fed-state in Older Men.

A Literature Review of Taste Change and Zinc Deficiency After Bariatric Surgery: Could There Be a Causal Link? (2022)
Journal Article
Mozaffar, B., & Idris, I. (2023). A Literature Review of Taste Change and Zinc Deficiency After Bariatric Surgery: Could There Be a Causal Link?. Obesity Surgery, 33, 313-331. https://doi.org/10.1007/s11695-022-06197-4

In this review, we collated evidence relating to taste change and zinc deficiency in relation to bariatric surgery (BS) and effects of zinc replacement on taste perception and speculate on the possible role of zinc deficiency to induce taste change a... Read More about A Literature Review of Taste Change and Zinc Deficiency After Bariatric Surgery: Could There Be a Causal Link?.

Caloric restriction improves glycaemic control without reducing plasma branched-chain amino acids or keto-acids in obese men (2022)
Journal Article
Sayda, M. H., Abdul-Aziz, M. H., Gharahdaghi, N., Wilkinson, D. J., Greenhaff, P. L., Philips, B. E., …Atherton, P. J. (2022). Caloric restriction improves glycaemic control without reducing plasma branched-chain amino acids or keto-acids in obese men. Scientific Reports, 12, Article 19273. https://doi.org/10.1038/s41598-022-21814-z

Higher plasma leucine, isoleucine and valine (BCAA) concentrations are associated with diabetes, obesity and insulin resistance (IR). Here, we evaluated the effects of 6-weeks very-low calorie diet (VLCD) upon fasting BCAA in overweight (OW) non-diab... Read More about Caloric restriction improves glycaemic control without reducing plasma branched-chain amino acids or keto-acids in obese men.

The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis (2022)
Journal Article
Ramzan, I., Ardavani, A., Vanweert, F., Mellett, A., Atherton, P. J., & Idris, I. (2022). The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis. Nutrients, 14(20), Article 4411. https://doi.org/10.3390/nu14204411

Introduction: Recent studies have concluded that elevated circulating branched chain amino acids (BCAA) are associated with the pathogenesis of type 2 diabetes mellitus (T2DM) and obesity. However, the development of this association over time and th... Read More about The Association between Circulating Branched Chain Amino Acids and the Temporal Risk of Developing Type 2 Diabetes Mellitus: A Systematic Review & Meta-Analysis.

Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies (2022)
Journal Article
Crabtree, T., Ogendo, J. J., Vinogradova, Y., Gordon, J., & Idris, I. (2022). Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert Review of Endocrinology and Metabolism, https://doi.org/10.1080/17446651.2022.2079495

Introduction: Guidelines for type 2 diabetes (T2D) recommend individualized HbA1c targets to take into account patient age or frailty. We synthesized evidence from randomized controlled trials and observational studies for intensive glycemic control... Read More about Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies.

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists (2022)
Journal Article
Crabtree, T. S. J., Adamson, K., Reid, H., Barnes, D., Sivappriyan, S., Bickerton, A., …Ryder, R. E. J. (2022). Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes, Obesity and Metabolism, 24(7), 1398-1401. https://doi.org/10.1111/dom.14701

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor ago... Read More about Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.

Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes (2022)
Journal Article
Patel, R., Crabtree, T. S., Taylor, N., Langeland, L., Gazis, A. (., Mendis, B., …Idris, I. (2022). Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes. Diabetic Medicine, 39(5), Article e14793. https://doi.org/10.1111/dme.14793

Aims: The use of do-it-yourself artificial pancreas systems (DIYAPS) among people with type 1 diabetes is increasing. At present, it is unclear how DIYAPS compares with other technologies such as FreeStyle Libre (FSL) and continuous subcutaneous insu... Read More about Safety and effectiveness of do-it-yourself artificial pancreas system compared with continuous subcutaneous insulin infusions in combination with free style libre in people with type 1 diabetes.

Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation (2022)
Journal Article
Alshnbari, A., & Idris, I. (2022). Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation. Current Medical Research and Opinion, 38(3), 357-364. https://doi.org/10.1080/03007995.2022.2027141

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are antidiabetic drugs with numerous pleiotropic and positive clinical effects, particularly regarding a reno-cardiovascular protective effect. More recent studies, including from our laboratory, ha... Read More about Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?–Targeting hyperinflammation.